HC Wainwright Analysts Lower Earnings Estimates for Galectin Therapeutics Inc. (NASDAQ:GALT)

Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - HC Wainwright cut their FY2025 earnings per share estimates for shares of Galectin Therapeutics in a report issued on Monday, April 1st. HC Wainwright analyst E. Arce now forecasts that the company will post earnings of ($1.59) per share for the year, down from their previous forecast of ($1.37). HC Wainwright has a "Buy" rating and a $11.00 price target on the stock. The consensus estimate for Galectin Therapeutics' current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Galectin Therapeutics' FY2026 earnings at ($0.97) EPS and FY2027 earnings at $1.32 EPS.

Separately, StockNews.com upgraded Galectin Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday.

Galectin Therapeutics Stock Up 5.3 %

GALT stock traded up $0.15 during trading on Thursday, hitting $3.00. The company had a trading volume of 285,142 shares, compared to its average volume of 81,307. The firm has a market cap of $185.70 million, a PE ratio of -4.05 and a beta of 0.84. Galectin Therapeutics has a 1-year low of $1.28 and a 1-year high of $3.00. The firm has a 50-day moving average price of $2.00 and a 200-day moving average price of $1.93.

Hedge Funds Weigh In On Galectin Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Atria Wealth Solutions Inc. acquired a new stake in shares of Galectin Therapeutics in the 1st quarter worth approximately $460,000. Osaic Holdings Inc. lifted its stake in Galectin Therapeutics by 12.9% in the 2nd quarter. Osaic Holdings Inc. now owns 1,435,557 shares of the company's stock valued at $2,067,000 after buying an additional 163,797 shares in the last quarter. Solutions 4 Wealth Ltd purchased a new stake in Galectin Therapeutics in the 4th quarter valued at approximately $60,000. Jane Street Group LLC purchased a new stake in Galectin Therapeutics in the 4th quarter valued at approximately $40,000. Finally, Traynor Capital Management Inc. purchased a new stake in Galectin Therapeutics in the 3rd quarter valued at approximately $67,000. Institutional investors and hedge funds own 11.68% of the company's stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.